Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up

Transplant International

Volumn 23, Issue 2, 2010, Pages 147-154

  Lee, Yu Ji ^a   Kim, Beom ^b   Lee, Jung Eun ^a   Kim, Yoon Goo ^a   Kim, Dae Joong ^a   Kim, Sung Joo ^a   Joh, Jae Won ^a   Oh, Ha Young ^a   Huh, Wooseong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul Veterans Hospital   (South Korea)

Author keywords

Cyclosporine; Graft survival; Kidney transplantation; Steroids; Tacrolimus

Indexed keywords

CIPOL; CIPOL N; CREATININE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; AVASCULAR NECROSIS; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GINGIVA HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER FUNCTION TEST; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; CYCLOSPORINE; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; STEROIDS; TACROLIMUS;

EID: 73449146995     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00955.x     Document Type: Article

References (45)

1. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999 33 : 829.
2. Fryer JP, Granger DK, Leventhal JR, Gillingham K, Najarian JS, Matas AJ. Steroid-related complications in the cyclosporine era. Clin Transplant 1994 8 : 224.
3. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000 11 : 1910.
4. Sinclair NR. Low-dose steroid therapy in cyclos6porine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992 147 : 645.
5. Pelletier RP, Akin B, Ferguson RM. Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine. Clin Transplant 2006 20 : 10.
6. Pascual J, van Hooff JP, Salmela K, Lang P, Rigotti P, Budde K. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006 82 : 55.
7. Wlodarczyk Z, Walaszewski J, Perner F, et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. Ann Transplant 2002 7 : 28.
8. Park JB, Kim SJ, Oh HY, et al. Steroid withdrawal in living donor renal transplant recipients using tacrolimus and cyclosporine: a randomized prospective study. Transpl Int 2006 19 : 478.
9. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993 55 : 752.
10. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997 64 : 436.
11. Augustine JJ, Hricik DE. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 2006 1 : 1080.
12. Teraoka S, Sato S, Sekijima M, et al. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid. Transplant Proc 2005 37 : 791.
13. Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001 72 : 845.
14. Matas AJ. Minimization of steroids in kidney transplantation. Transpl Int 2009 22 : 38.
15. Opelz G, Naujokat C, Daniel V, Terness P, Dohler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006 81 : 1227.
16. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 2006 20 : 401.
17. Matl I, Lacha J, Lodererova A, et al. Withdrawal of steroids from triple-drug therapy in kidney transplant patients. Nephrol Dial Transplant 2000 15 : 1041.
18. Hricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroids after renal transplantation - clinical predictors of outcome. Transplantation 1992 53 : 41.
19. Maes BD, Claes K, Coosemans W, et al. Cessation of steroids in stable renal transplant patients: the Leuven experience. Clin Transpl 2002 181.
20. Budde K, Geissler S, Hallebach G, et al. Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up. Transplant Proc 2002 34 : 1703.
21. Dunn TB, Asolati M, Holman DM, et al. Long-term outcome of a prospective trial of steroid withdrawal after kidney transplantation. Surgery 1999 125 : 155.
22. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005 331 : 810.
23. Kramer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005 20 : 968.
24. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003 75 : 2048.
25. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002 73 : 775.
26. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002 359 : 741.
27. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999 318 : 1104.
28. Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis 2001 38 : S44.
29. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996 49 : 518.
30. Carvalho MF, Soares V. Hyperlipidemia as a risk factor of renal allograft function impairment. Clin Transplant 2001 15 : 48.
31. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998 53 : 217.
32. Artz MA, Boots JM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004 4 : 937.
33. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001 12 : 368.
34. Koomans HA, Ligtenberg G. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 2001 72 : S9.
35. Massy ZA, Kasiske BL. Post-transplant hyperlipidemia: mechanisms and management. J Am Soc Nephrol 1996 7 : 971.
36. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003 3 : 178.
37. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004 4 : 583.
38. Ghisdal L, Bouchta NB, Broeders N, et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008 21 : 146.
39. van Duijnhoven EM, Boots JM, Christiaans MH, van Hooff JP. Metabolic aspects of tacrolimus in renal transplantation. Consequences for the choice of an immunosuppressive regimen and for the management of post-transplant diabetes mellitus. Minerva Urol Nefrol 2003 55 : 33.
40. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002 13 : 1374.
41. Baid S, Tolkoff-Rubin N, Farrell ML, et al. Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis C infection. Transplant Proc 2002 34 : 1771.
42. Levine E, Erken EH, Price HI, Meyers AM, Solomon L. Osteonecrosis following renal transplantation. AJR Am J Roentgenol 1977 128 : 985.
43. Hedri H, Cherif M, Zouaghi K, et al. Avascular osteonecrosis after renal transplantation. Transplant Proc 2007 39 : 1036.
44. Abbott KC, Koff J, Bohen EM, et al. Maintenance immunosuppression use and the associated risk of avascular necrosis after kidney transplantation in the United States. Transplantation 2005 79 : 330.
45. McDonald S, Russ G, Campbell S, Chadban S. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant 2007 7 : 1201.